MA31084B1 - Derives de piperidine agonistes de gpcr - Google Patents
Derives de piperidine agonistes de gpcrInfo
- Publication number
- MA31084B1 MA31084B1 MA32072A MA32072A MA31084B1 MA 31084 B1 MA31084 B1 MA 31084B1 MA 32072 A MA32072 A MA 32072A MA 32072 A MA32072 A MA 32072A MA 31084 B1 MA31084 B1 MA 31084B1
- Authority
- MA
- Morocco
- Prior art keywords
- piperidine derivatives
- gpcr agonist
- gpcr
- agonist
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I) : OU DES SELS ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE DE CEUX-CI, QUI SONT DES AGONISTES DE GPCR ET S'UTILISENT POUR LE TRAITEMENT DE L'OBÉSITÉ ET DU DIABÈTE.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700124A GB0700124D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
GB0708740A GB0708740D0 (en) | 2007-05-08 | 2007-05-08 | Gpcr agonists |
GB0719762A GB0719762D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31084B1 true MA31084B1 (fr) | 2010-01-04 |
Family
ID=39203222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32072A MA31084B1 (fr) | 2007-01-04 | 2009-07-03 | Derives de piperidine agonistes de gpcr |
Country Status (28)
Country | Link |
---|---|
US (1) | US20100022591A1 (fr) |
EP (2) | EP2114931B1 (fr) |
JP (1) | JP2010514829A (fr) |
KR (1) | KR20090104092A (fr) |
CN (1) | CN101627036A (fr) |
AR (1) | AR064736A1 (fr) |
AT (1) | ATE531710T1 (fr) |
AU (1) | AU2008203673A1 (fr) |
BR (1) | BRPI0806468A2 (fr) |
CA (1) | CA2674093A1 (fr) |
CL (1) | CL2008000017A1 (fr) |
DK (1) | DK2114931T3 (fr) |
EA (1) | EA015805B9 (fr) |
ES (1) | ES2376015T3 (fr) |
HK (1) | HK1135704A1 (fr) |
HR (1) | HRP20110964T1 (fr) |
IL (1) | IL199680A0 (fr) |
MA (1) | MA31084B1 (fr) |
MX (1) | MX2009007180A (fr) |
NZ (1) | NZ578144A (fr) |
PE (1) | PE20081849A1 (fr) |
PL (1) | PL2114931T3 (fr) |
PT (1) | PT2114931E (fr) |
RS (1) | RS52168B (fr) |
SA (1) | SA08280756B1 (fr) |
SI (1) | SI2114931T1 (fr) |
TW (1) | TWI380818B (fr) |
WO (1) | WO2008081205A1 (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
JP4980928B2 (ja) * | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用 |
WO2007003962A2 (fr) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes de gpcr |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
AR064735A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
CN101868452B (zh) | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812642D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
JP5309216B2 (ja) * | 2008-07-11 | 2013-10-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性のモジュレーターとしての4−フェノキシメチルピペリジン類 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
WO2011019538A1 (fr) | 2009-08-13 | 2011-02-17 | Merck Sharp & Dohme Corp. | Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
WO2011113947A1 (fr) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
ITMI20100770A1 (it) | 2010-05-03 | 2011-11-04 | Dipharma Francis Srl | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi |
NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
ITMI20100984A1 (it) | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
CA2831334A1 (fr) * | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Composes a cyclopropyle substitue, compositions contenant de tels composes et methodes de traitement |
JP6463631B2 (ja) | 2011-06-09 | 2019-02-06 | ライゼン・ファーマシューティカルズ・エスアー | Gpr−119のモジュレータとしての新規化合物 |
US9006228B2 (en) | 2011-06-16 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
EP3517539B1 (fr) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Dérivé de quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement du diabète de type i et ii |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
EP2760855B1 (fr) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Composés de cyclopropyle substitués, compositions contenant ces composés ainsi que leur utilisation pour le traitement du diabète de type 2 |
WO2013062838A1 (fr) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119 |
JP6101279B2 (ja) | 2011-11-15 | 2017-03-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Gpr119アゴニストとして有用な置換シクロプロピル化合物 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (fr) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique |
WO2013174767A1 (fr) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
KR101726819B1 (ko) | 2014-10-27 | 2017-04-13 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
EP3468562A1 (fr) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinaisons de linagliptine et de metformine |
EP3421455B1 (fr) * | 2017-06-29 | 2019-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Procédé amélioré pour la préparation de3-amino-piperidins chiraux, des intermédiaires utiles pour la préparation de tofacitinib |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
FR2705346B1 (fr) * | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
ES2140543T3 (es) | 1993-08-13 | 2000-03-01 | Zeneca Ltd | Derivados de tia- y oxadiazol y su uso como fungicidas o insecticidas. |
WO1997015567A1 (fr) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants |
WO1998006720A1 (fr) * | 1996-08-09 | 1998-02-19 | Eisai Co., Ltd. | Derives de benzopiperidine |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
EP1123391A2 (fr) | 1998-09-01 | 2001-08-16 | BASF Aktiengesellschaft | Methodes permettant d'ameliorer la fonction des recepteurs heterologues couples a la proteine g |
US6221660B1 (en) * | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
WO2002042274A1 (fr) * | 2000-11-21 | 2002-05-30 | Mitsubishi Chemical Corporation | Procede de production de 2-(4-pyridyl)ethanethiol |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
KR100950430B1 (ko) | 2001-09-21 | 2010-04-02 | 솔베이 파마슈티칼스 비. 브이 | 효력있는 cb1-길항 작용을 가지는4,5-디하이드로-1h-피라졸 유도체 |
DK1429761T3 (da) | 2001-09-21 | 2007-02-05 | Solvay Pharm Bv | Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning |
FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
WO2003063781A2 (fr) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Imidazoles substitues en tant que modulateurs du recepteur cannabinoide |
EP1482794A1 (fr) | 2002-03-06 | 2004-12-08 | Merck & Co., Inc. | Methode de traitement ou de prevention de l'obesite |
CA2478183C (fr) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Amides substitues |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
CA2479744A1 (fr) | 2002-03-28 | 2003-10-09 | Paul E. Finke | 2,3-diphenyl-pyridines substituees |
EP1494997A4 (fr) | 2002-04-05 | 2007-04-11 | Merck & Co Inc | Arylamides substituee |
FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
JP4459629B2 (ja) | 2002-04-12 | 2010-04-28 | メルク エンド カムパニー インコーポレーテッド | 二環式アミド |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
WO2004013120A1 (fr) | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Nouveaux benzodioxoles |
JP4667867B2 (ja) | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換フロ[2,3−b]ピリジン誘導体 |
AU2003296895A1 (en) | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
AR041268A1 (es) | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen |
EP1546115A4 (fr) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | Pyrimidines substituees |
CA2502511A1 (fr) | 2002-10-18 | 2004-05-29 | Pfizer Products Inc. | Ligands des recepteurs des cannabinoides et applications de ceux-ci |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AU2003300967B2 (en) | 2002-12-19 | 2009-05-28 | Merck Sharp & Dohme Corp. | Substituted amides |
GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
ES2334565T3 (es) | 2003-01-02 | 2010-03-12 | Hoffmann La Roche | Agonistas inversos del receptor cb 1. |
PL378244A1 (pl) | 2003-01-02 | 2006-03-20 | F. Hoffmann-La Roche Ag | Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1 |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
EP1597259B1 (fr) | 2003-02-13 | 2008-04-30 | Sanofi-Aventis Deutschland GmbH | Derives de hexahydro-pyrazino 1,2-a pyrimidine-4,7-diones a substitution azote, procedes de fabrication et utilisation en tant qu'agents pharmaceutiques |
EP1599480B1 (fr) | 2003-02-13 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Derives de hexahydro-pyrazino(1,2-a)pyrimidine-4,7-diones substitues, procedes de fabrication et utilisation en tant qu'agents pharmaceutiques |
US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
EP1606019A1 (fr) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Agonistes inverses de recepteurs de cannabinoides et antagonistes neutres agissant en tant qu'agents therapeutiques destines au traitement de troubles osseux |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
KR101154830B1 (ko) | 2003-12-24 | 2012-06-18 | 프로시디온 리미티드 | Gpcr 수용체 효능제로서의 헤테로사이클릭 유도체 |
JP4980928B2 (ja) * | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用 |
JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Gタンパク質結合受容体作動薬 |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
WO2007003962A2 (fr) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes de gpcr |
US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
KR20080025190A (ko) | 2005-06-30 | 2008-03-19 | 프로시디온 리미티드 | G-단백질 결합된 수용체 효능제 |
WO2007003960A1 (fr) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes du gpcr |
WO2007116229A1 (fr) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Agonistes gpcr hétérocycliques |
MX2009005935A (es) * | 2006-12-06 | 2009-06-30 | Smithkline Beecham Corp | Compuestos biciclicos y su uso como anti-diabeticos. |
RS52065B (en) * | 2007-01-04 | 2012-06-30 | Prosidion Ltd | PIPERIDINSKI GPCR AGONIST |
CA2674360A1 (fr) * | 2007-01-04 | 2008-07-10 | Prosidion Limited | Agonistes de gpcr piperidiniques |
AR064735A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
-
2008
- 2008-01-03 PE PE2008000085A patent/PE20081849A1/es not_active Application Discontinuation
- 2008-01-03 CL CL200800017A patent/CL2008000017A1/es unknown
- 2008-01-03 AR ARP080100018A patent/AR064736A1/es not_active Application Discontinuation
- 2008-01-04 CN CN200880007091A patent/CN101627036A/zh active Pending
- 2008-01-04 NZ NZ578144A patent/NZ578144A/en not_active IP Right Cessation
- 2008-01-04 KR KR1020097016214A patent/KR20090104092A/ko not_active Application Discontinuation
- 2008-01-04 EA EA200900796A patent/EA015805B9/ru not_active IP Right Cessation
- 2008-01-04 WO PCT/GB2008/050011 patent/WO2008081205A1/fr active Application Filing
- 2008-01-04 PL PL08700184T patent/PL2114931T3/pl unknown
- 2008-01-04 EP EP08700184A patent/EP2114931B1/fr active Active
- 2008-01-04 EP EP11172885A patent/EP2383270A1/fr not_active Withdrawn
- 2008-01-04 ES ES08700184T patent/ES2376015T3/es active Active
- 2008-01-04 US US12/522,018 patent/US20100022591A1/en not_active Abandoned
- 2008-01-04 CA CA002674093A patent/CA2674093A1/fr not_active Abandoned
- 2008-01-04 PT PT08700184T patent/PT2114931E/pt unknown
- 2008-01-04 RS RS20120031A patent/RS52168B/en unknown
- 2008-01-04 BR BRPI0806468-7A patent/BRPI0806468A2/pt not_active IP Right Cessation
- 2008-01-04 TW TW097100419A patent/TWI380818B/zh not_active IP Right Cessation
- 2008-01-04 SI SI200830517T patent/SI2114931T1/sl unknown
- 2008-01-04 AT AT08700184T patent/ATE531710T1/de active
- 2008-01-04 JP JP2009544448A patent/JP2010514829A/ja active Pending
- 2008-01-04 AU AU2008203673A patent/AU2008203673A1/en not_active Abandoned
- 2008-01-04 DK DK08700184.8T patent/DK2114931T3/da active
- 2008-01-04 MX MX2009007180A patent/MX2009007180A/es active IP Right Grant
- 2008-01-05 SA SA8280756A patent/SA08280756B1/ar unknown
-
2009
- 2009-07-02 IL IL199680A patent/IL199680A0/en unknown
- 2009-07-03 MA MA32072A patent/MA31084B1/fr unknown
-
2010
- 2010-04-16 HK HK10103732.5A patent/HK1135704A1/xx not_active IP Right Cessation
-
2011
- 2011-12-21 HR HR20110964T patent/HRP20110964T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT2114931E (pt) | 2012-01-12 |
BRPI0806468A2 (pt) | 2011-09-27 |
ATE531710T1 (de) | 2011-11-15 |
MX2009007180A (es) | 2009-07-15 |
KR20090104092A (ko) | 2009-10-05 |
CL2008000017A1 (es) | 2008-08-01 |
AU2008203673A1 (en) | 2008-07-10 |
EA200900796A1 (ru) | 2010-02-26 |
SI2114931T1 (sl) | 2012-02-29 |
ES2376015T3 (es) | 2012-03-08 |
HK1135704A1 (en) | 2010-06-11 |
CA2674093A1 (fr) | 2008-07-10 |
NZ578144A (en) | 2011-03-31 |
WO2008081205A1 (fr) | 2008-07-10 |
IL199680A0 (en) | 2010-04-15 |
PL2114931T3 (pl) | 2012-03-30 |
EP2114931A1 (fr) | 2009-11-11 |
PE20081849A1 (es) | 2009-01-26 |
SA08280756B1 (ar) | 2011-01-24 |
EA015805B9 (ru) | 2012-03-30 |
DK2114931T3 (da) | 2012-02-13 |
TWI380818B (zh) | 2013-01-01 |
HRP20110964T1 (hr) | 2012-01-31 |
AR064736A1 (es) | 2009-04-22 |
US20100022591A1 (en) | 2010-01-28 |
CN101627036A (zh) | 2010-01-13 |
RS52168B (en) | 2012-08-31 |
TW200835489A (en) | 2008-09-01 |
JP2010514829A (ja) | 2010-05-06 |
EA015805B1 (ru) | 2011-12-30 |
EP2114931B1 (fr) | 2011-11-02 |
EP2383270A1 (fr) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
BRPI0513433A (pt) | derivados de hidantoìna para o tratamento de distúrbios inflamatórios | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
NO20083480L (no) | Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
EA200970612A1 (ru) | Производные индола в качестве агонистов рецептора s1p1 | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA31766B1 (fr) | Composés organiques | |
CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
MA30694B1 (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. | |
NO20076479L (no) | Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer | |
EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
MA32965B1 (fr) | Derives de sulfonamides | |
MA28077A1 (fr) | Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes | |
NO20084318L (no) | Inhibitorer av II-beta-hydroksystereoid dehydrogenase I | |
TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
BRPI0515628A (pt) | composto de 2-morfolina-4-pirimidona | |
MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 |